Articles tagged with Crohn Disease
Researchers found that a specific virus interacts with a mutation in the host's genes to trigger disease. In mice, exposure to a damaging chemical and infection with a viral strain caused symptoms similar to human Crohn's disease, suggesting viruses may be key to understanding complex diseases.
Researchers at McMaster University have identified a chemical, prostaglandin D2, that may trigger remission in patients with ulcerative colitis. Elevated levels of this chemical were found in patients in long-term remission, suggesting it as a key factor in preventing new episodes.
Researchers at Duke Clinical Research Institute found that telaprevir significantly improves response rates in patients with difficult-to-treat hepatitis C cases. The study also suggests a potential link between aspirin use and the development of inflammatory bowel disease, including Crohn's disease.
A new study by the University of East Anglia found that regular aspirin use increases the risk of developing Crohn's disease by five times. The research, which followed 200,000 volunteers, suggests that aspirin may be a contributing factor to the development of this debilitating condition.
A study published in the New England Journal of Medicine found that patients with moderate to severe Crohn's disease who received combination therapy with infliximab and azathioprine had a higher chance of achieving remission compared to those treated with azathioprine alone. The researchers also discovered comparable safety results ac...
A new study of 43,596 Danish individuals found no statistically significant link between specific genetic variants and an increased risk of Crohn's disease. The study suggests that the effect of these genetic variants on disease risk is likely to be low, challenging personalized medicine approaches.
A signaling protein, GM-CSF, plays a vital role in fighting bacterial infections and inflammation in the intestinal tract. Its deficiency is linked to increased susceptibility to persistent gut infection, severe inflammation, and disease duration.
Researchers have identified genetic risk markers for post-infectious irritable bowel syndrome (PI-IBS) in victims of the Walkerton tainted drinking water tragedy. The study, led by McGill PhD Alexandra-Chloé Villani, found that genetic factors play a critical role in the development of PI-IBS.
A new study published in Journal of Biological Chemistry found that Vitamin D deficiency can contribute to Crohn's disease. The researchers discovered that Vitamin D acts directly on genes involved in fighting intestinal bacteria and immune responses. Siblings of patients with Crohn's disease may benefit from ensuring they are vitamin ...
A clinical trial at the University of Western Ontario aims to improve patient treatment for Crohn's disease by evaluating a new combination therapy approach. The REACT study will compare conventional management strategies to a newer paradigm featuring early use of immunosuppression and anti-metabolites.
Researchers have identified a critical imbalance of regulatory cells and increased 'attack' cells in people with Crohn's disease and ulcerative colitis. This imbalance can be addressed through diet and lifestyle changes, reducing the need for colonoscopies.
A study found that patients with IBD, particularly those on thiopurine medications, may be at higher risk for non-melanoma skin cancer. The study also showed that recent use of immunosuppressive medications was associated with increased risk of NMSC.
A cohort study of 19,486 patients with inflammatory bowel disease found a significant increased risk of lymphoma associated with thiopurine use. The absolute cumulative risk remains low in young patients, but elderly patients and prolonged treatment periods warrant further investigation.
A study has found that a mutation in the NOD2 gene may predispose individuals to Crohn's disease by impairing the immune system's ability to recognize and fight off mycobacteria. The research, published in the Journal of Experimental Medicine, highlights the potential for new therapeutic approaches to combat the disease.
Researchers presented data on the effectiveness of monoclonal antibodies in treating Crohn's disease and preventing C. difficile recurrence, showing improved clinical outcomes and safety profiles.
Researchers explore health outcomes of IBD, finding increased radiation exposure among patients, especially those with Crohn's disease. Growth hormone therapy shows promise in reducing symptoms and improving disease activity in pediatric CD patients.
Researchers at Brown University found MR enterography to be an effective tool for evaluating and guiding treatment of Crohn's Disease patients without exposing them to unnecessary radiation. The test was shown to provide valuable information for guiding patient management, with physicians overwhelmingly preferring it over CT scans.
Researchers have discovered new genes involved in Crohn's disease using a novel approach that combines statistical tools and automated gene-hunting techniques. The study identified genes on the same biological pathways as those already known to be relevant to the biology of Crohn's disease.
A new study found that infliximab was effective at preventing endoscopic, clinical and histological postoperative recurrence of Crohn's disease. The treatment significantly reduced the rate of endoscopic recurrence (9.1%) compared to placebo (84.6%).
Researchers at McGill University have discovered a DNA variation in the NLRP3 gene that increases susceptibility to developing Crohn's disease. The study reveals how a faulty bacterial sensor disrupts the digestive immune system's defense against harmful bacteria, leading to chronic inflammation and disease.
A Mayo Clinic-led study finds that infliximab administered alone or in combination with azathioprine is more effective for moderate to severe Crohn's disease than azathioprine alone. The study demonstrates improved patient outcomes, including higher remission rates and mucosal healing.
Research finds disabled gut cells linked to Crohn's disease, with altered genetic activity leading to increased hormone production. The study suggests a potential role for autophagy and Atg16L1 in Paneth cell function, shedding light on the complex mechanisms behind the inflammatory bowel disorder.
A study has identified a new gene that may play a key role in the development of pediatric-onset inflammatory bowel disease. The gene, TNFRSF6B, is involved in regulating inflammation and its activity has been linked to the severity of the disease.
Researchers are developing new treatments targeting Crohn's disease by blocking autoimmune responses and strengthening the intestinal lining. The goal is to provide more effective options for patients who have lost response to current treatments.
Researchers at Montreal Heart Institute and Mount Sinai Hospital discover 21 new genetic risk factors associated with Crohn's disease, more than doubling the amount of genetic information about the disease. This breakthrough study offers hope for better-targeted therapy for millions of people with inflammatory bowel diseases.
An international team of researchers has identified 21 new genetic risk factors for Crohn's disease, building on earlier studies that linked the disorder to disruptions in autophagy and immune system response. The findings, published in Nature Genetics, may lead to novel therapies and prevention strategies.
A study published in Nature Genetics has identified over 30 genetic regions associated with Crohn's disease, revealing surprising links between the condition and other common diseases like asthma. The research also highlights the complexity of the disease, suggesting hundreds of genes may be involved.
Researchers are investigating the effectiveness of dietary changes and complementary medicine to control inflammatory bowel diseases (IBD) flare-ups. The studies aim to find alternative treatments with fewer side effects, targeting stress reduction and gut bacteria balance.
A new analysis of REMICADE for ulcerative colitis found that over 60% of patients achieved clinical response at week 8, with significant improvements maintained at week 30. The study also reported significant improvements in disease remission and mucosal healing.
A large-scale study published in Journal of the American Medical Association finds that omega-3 fatty acids offer no benefit for preventing relapse in Crohn's disease. However, patients who took omega-3 supplements experienced significantly lower triglyceride levels, a risk factor for heart disease.
A large-scale study found that omega-3 free fatty acid supplements did not significantly reduce the risk of relapse in patients with Crohn disease. The research, published in JAMA, evaluated the effectiveness of high-dose omega-3 fatty acids as maintenance therapy in patients with Crohn disease in remission.
A large multicenter study suggests new genetic markers for Crohn's disease, specifically affecting the Ashkenazi Jewish population. The study found evidence of genes causing familial Crohn's Disease on chromosomes 1 and 3, as well as a previously unidentified region on chromosome 13.
A case report describes a woman with small bowel endometriosis who presented symptoms similar to Crohn's disease. Histopathological examination confirmed the diagnosis of Crohn's disease, highlighting the need for accurate differential diagnosis in clinical practice.
Researchers found that combined immunosuppression therapy was more effective than conventional treatment in inducing remission and reducing corticosteroid use in patients with newly diagnosed Crohn's disease. The study showed that early intensive treatment could lead to better outcomes, with higher remission rates at weeks 26 and 52.
Researchers found that a new 'top-down' therapy approach significantly improved disease remission rates and reduced steroid use in Crohn's patients. The two-year study showed 60% of top-down subjects were symptom-free by week 26, compared to 36% on traditional step-up treatment.
Researchers found that Mycobacterium paratuberculosis, a bacterium causing cattle illness, triggers Crohn's disease in humans by releasing a molecule preventing white blood cells from killing E.coli bacteria. The team suggests dairy products, including cow milk, may be the entry point for this bacterium.
Two studies found that genetic variants in metabolic genes impact cholesterol metabolism, while Crohn's disease contributes to atherosclerosis. Researchers also identified a potential treatment for bile acid disorders using FXR targeted therapies.
REMICADE has been used to treat more patients worldwide than all other anti-TNF-alpha agents combined. The treatment of patients with inflammatory diseases, such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis and Crohn's disease, has been transformed by the availability of REMICADE.
Researchers used capsule endoscopy to evaluate unexplained gastrointestinal bleeding and found six previously undiagnosed cases of Crohn's disease. The study highlights the tool's ability to detect inflammation in the small intestine, which can be missed by colonoscopies.
A study published by the American Society for Gastrointestinal Endoscopy found that capsule endoscopy identified Crohn's disease recurrence in 62% of patients, compared to 25% with colonoscopy. This led to changes in therapy for more than half of the patients studied.
A recent study published in The ISME Journal reveals that a specific group of E. coli bacteria is associated with chronic intestinal inflammation in patients with Crohn's disease. Researchers found an increased level of invasive E. coli bacteria in inflamed areas of the small intestine, suggesting a potential causal link to the disease.
Researchers at Children's Hospital of Philadelphia identified a gene variant associated with an increased risk of Crohn's disease in children. The study found that 64% of children with the disease had a specific variant form of the ATG16L1 gene, compared to 52% of healthy children.
A new therapy, certolizumab pegol, has been found to be effective in easing symptoms of patients with active Crohn's disease. The treatment was shown to improve clinical symptoms in both short-term and long-term maintenance therapies, offering a potential new option for managing the condition.
Patients with ankylosing spondylitis who received REMICADE showed significant improvement in spinal mobility and reduced spinal inflammation over two years. This study found that REMICADE-treated patients experienced sustained reductions in spinal inflammation, as detected by magnetic resonance imaging (MRI), compared to placebo group.
A new study demonstrates the value of PET/CT in diagnosing and monitoring Crohn's disease, offering a non-invasive alternative to invasive endoscopy. The scan can accurately identify active disease and detect severe lesions, reducing the need for costly and side-effect-ridden treatments.
A Phase II clinical trial suggests that extracorporeal photopheresis (ECP) is effective in treating clinically active Crohn's disease, with a 50% response rate after 3 months of treatment. Patients who responded to ECP therapy experienced notable improvements in disease symptoms and signs within six weeks.
Researchers discovered that CEACAM6 facilitates adhesion of adherent-invasive E. coli (AIEC) bacteria to the intestinal epithelial cells' brush border in patients with Crohn's disease. This adhesion is dependent on CEACAM6 expression, which is increased in Crohn's disease patients after infection.
A long-term study of REMICADE found that patients with moderate to severe ulcerative colitis maintained improved clinical symptoms for up to two years after treatment. The study showed that 92% of patients had mild or no disease activity at week 56 and 97% at week 104, indicating sustained efficacy.
A study by Mayo Clinic found that adalimumab is an effective treatment for adults with Crohn’s disease who do not respond to infliximab therapy. The therapy was shown to achieve remission in 21% of patients and improve symptoms in 52%.
Researchers have discovered a new genetic locus associated with an increased risk of developing Crohn's disease, a chronic inflammatory disorder. The study, published in PLOS Genetics, found that a specific region on chromosome 5 is linked to the disease.
A consortium of Canadian and American researchers have identified three major genetic risk factors for Crohn's disease: PHOX2B, NCF4, and ATG16L1. These findings highlight biological pathways not previously thought to play a role in the disease, including altered reactive oxygen species production and autophagic processes.
A study published in Nature Genetics identifies PHOX2B, NCF4, and ATG16L1 as genetic risk factors for Crohn's disease. The research highlights the role of neuroendocrine cells and altered reactive oxygen species production in increasing disease susceptibility.
Researchers identify three genetic variants associated with an increased risk of Crohn's disease, including PHOX2B, NCF4, and ATG16L1. These discoveries offer new insights into the biological pathways underlying the disease and may lead to more effective therapies.
A research team has identified several novel genetic variations associated with the risk of Crohn's disease, which could improve understanding of the disease process and lead to new therapies. The study found that one of the newly identified genes, ATG16L1, plays a crucial role in autophagy, a biological pathway involved in inflammation.
Patients treated with REMICADE experienced significant improvements in work and daily activities, with mean increases of 2.9-3.1 points compared to little improvement in placebo-treated patients. Psoriasis is an inflammatory disorder that can cause physical pain and emotional distress, impacting productivity.
A Penn State College of Medicine pilot study found that 89 percent of participants with diagnosed Crohn's disease showed improvement with low-dose naltrexone therapy, while 67 percent achieved remission. This novel approach offers a simple and safe treatment option for the chronic inflammatory disorder.
Research reveals IBD increases risk of premature birth and low birthweight by almost twice, while also boosting caesarean section rates and congenital defects
A CCFA survey reveals that 65% of ulcerative colitis patients are less than fully compliant with first-line therapies, resulting in a significant impact on their quality of life. The most common reasons for non-compliance were dosing frequency, number of pills, and medication inconvenience.
A recent study has identified a new genetic link to Crohn's disease, revealing that mutations in the IL-23 receptor gene are strongly associated with the condition. The researchers found that one type of mutation provides significant protection, paving the way for more individualized and effective treatments.
A study by Yale researchers has identified a gene variant associated with Crohn's disease, which may offer new therapeutic targets for the condition. The discovery was made in collaboration with international researchers who scanned the genome of over 300,000 individuals to identify genetic components of inflammatory bowel disease.